Hall-Flavin et al. first evaluated the potential change in clinical outcomes by utilizing GeneSight testing that measures allelic variation among five genes (CYP2D6, CYP2C19, CYP1A2, SLC6A4, and HTR2A) in a small sample size of patients with MDD. Here, CYP1A2 is linked to major depressive disorder.